



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

31 October 2019
EMA/COMP/564928/2019
Inspections, Human Medicines Pharmacovigilance and Committees Division

Committee for Orphan Medicinal Products (COMP)

Draft agenda for the meeting on 05-07 November 2019

Chair: Violeta Stoyanova-Beninska – Vice-Chair: Armando Magrelli

05 November 2019, 09:00-19:30, room 2A

06 November 2019, 08:30-19:30, room 2A

07 November 2019, 08:30-13:30, room 2A

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the COMP meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for COMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European
Union



Table of contents

1.	Introduction	5
1.1.	Welcome and declarations of interest of members and experts.....	5
1.2.	Adoption of agenda.....	5
1.3.	Adoption of the minutes	5
2.	Applications for orphan medicinal product designation	5
2.1.	For opinion	5
2.1.1.	-EMA/OD/0000010330	5
2.1.2.	- EMA/OD/0000014060	5
2.1.3.	- EMA/OD/0000012403	5
2.1.4.	- EMA/OD/0000013983	5
2.1.5.	- EMA/OD/0000012386	6
2.1.6.	- EMA/OD/0000007338	6
2.1.7.	- EMA/OD/0000013557	6
2.1.8.	- EMA/OD/0000004414	6
2.2.	For discussion / preparation for an opinion.....	6
2.2.1.	-EMA/OD/0000005940	6
2.2.2.	- EMA/OD/0000007445	6
2.2.3.	- EMA/OD/0000009960	6
2.2.4.	- EMA/OD/0000010610	6
2.2.5.	- EMA/OD/0000014201	7
2.2.6.	- EMA/OD/0000014361	7
2.2.7.	- EMA/OD/0000014371	7
2.2.8.	- EMA/OD/0000015485	7
2.2.9.	- EMA/OD/0000015678	7
2.2.10.	- EMA/OD/0000015943	7
2.2.11.	- EMA/OD/0000016160	7
2.2.12.	- EMA/OD/0000016202	7
2.2.13.	- EMA/OD/0000016302	7
2.2.14.	- EMA/OD/0000016345	8
2.2.15.	- EMA/OD/0000016360	8
2.2.16.	- EMA/OD/0000016622	8
2.2.17.	- EMA/OD/0000016648	8
2.2.18.	- EMA/OD/0000016718	8
2.3.	Revision of the COMP opinions	8
2.4.	Amendment of existing orphan designations.....	8
2.5.	Appeal	8

2.5.1.	naltrexone - EMA/OD/0000020985	8
2.6.	Nominations	8
2.6.1.	New applications for orphan medicinal product designation - Appointment of COMP rapporteurs.....	8
2.7.	Evaluation on-going.....	9
3.	Requests for protocol assistance with significant benefit question	9
3.1.	Ongoing procedures	9
3.1.1.	-.....	9
3.2.	Finalised letters.....	9
3.2.1.	-.....	9
3.2.2.	-.....	9
3.2.3.	-.....	9
3.2.4.	-.....	9
3.2.5.	-.....	9
3.3.	New requests.....	10
3.3.1.	-.....	10
3.3.2.	-.....	10
4.	Review of orphan designation for orphan medicinal products at time of initial marketing authorisation	10
4.1.	Orphan designated products for which CHMP opinions have been adopted	10
4.2.	Orphan designated products for discussion prior to adoption of CHMP opinion	10
4.2.1.	Revlimid – lenalidomide - EMEA/H/C/000717/II/0107, EMA/OD/158/12, EU/3/12/1097, EMA/OD/0000005466	10
4.2.2.	– Osilodrostat - EMEA/H/C/004821, EMA/OD/099/14, EU/3/14/1345, EMA/OD/0000003092	10
4.2.3.	– enasidenib - EMEA/H/C/004324, EMA/OD/253/15, EU/3/16/1640, EMA/OD/000000742210	10
4.3.	Appeal	10
4.4.	On-going procedures	11
4.5.	Orphan Maintenance Reports.....	11
5.	Review of orphan designation for authorised orphan medicinal products at time marketing authorisation extension	11
5.1.	After adoption of CHMP opinion	11
5.2.	Prior to adoption of CHMP opinion	11
5.2.1.	Darzalex – daratumumab - EMEA/H/C/004077/II/0030, EMA/OD/038/13, EU/3/13/1153, EMA/OD/0000010020	11
5.3.	Appeal	11
5.4.	On-going procedures	11

6.	Application of Article 8(2) of the Orphan Regulation	11
7.	Organisational, regulatory and methodological matters	12
7.1.	Mandate and organisation of the COMP	12
7.1.1.	Strategic Review & Learning meeting – joint COMP/CAT/PDCO, 21-22 November 2019, Helsinki, Finland	12
7.1.2.	Protocol Assistance Working Group (PAWG)	12
7.2.	Coordination with EMA Scientific Committees or CMDh-v	12
7.2.1.	Recommendation on eligibility to PRIME – report	12
7.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	12
7.3.1.	Working Party with Patients’ and Consumers’ Organisations (PCWP)	12
7.3.2.	Working Party with Healthcare Professionals’ Organisations (HCPWP)	12
7.4.	Cooperation within the EU regulatory network	12
7.4.1.	European Commission	12
7.5.	Cooperation with International Regulators	13
7.5.1.	Food and Drug Administration (FDA)	13
7.5.2.	Japanese Pharmaceuticals and Medical Devices Agency (PMDA)	13
7.5.3.	Therapeutic Goods Administration (TGA), Australia	13
7.5.4.	Health Canada	13
7.6.	Contacts of the COMP with external parties and interaction with the Interested Parties to the Committee	13
7.7.	COMP work plan	13
7.8.	Planning and reporting	13
7.8.1.	List of all applications submitted/expected and the COMP rapporteurship distribution of valid applications submitted in 2019	13
7.8.2.	Overview of orphan marketing authorisations/applications	13
8.	Any other business	14
9.	Explanatory notes	14

1. Introduction

1.1. Welcome and declarations of interest of members and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the COMP plenary session to be held 05-07 November 2019. See November 2019 COMP minutes (to be published post December 2019 COMP meeting).

1.2. Adoption of agenda

COMP agenda for 05-07 November 2019.

1.3. Adoption of the minutes

COMP minutes for 8-10 October 2019.

2. Applications for orphan medicinal product designation

2.1. For opinion

2.1.1. - [EMA/OD/0000010330](#)

Treatment of immune thrombocytopenia

Action: For adoption, Oral explanation to be held on 05 November 2019 at 09:30

2.1.2. - [EMA/OD/0000014060](#)

Treatment of amyotrophic lateral sclerosis

Action: For adoption, Oral explanation to be held on 05 November 2019 at 15:30

2.1.3. - [EMA/OD/0000012403](#)

Treatment of pancreatic cancer

Action: For information

Note: Withdrawal request received on 21 October 2019.

2.1.4. - [EMA/OD/0000013983](#)

Treatment of GM1 gangliosidosis

Action: For information

Note: Withdrawal request received on 15 October 2019.

2.1.5. - [EMA/OD/0000012386](#)

Treatment of Duchenne muscular dystrophy

Action: For adoption, Oral explanation to be held on 06 November 2019 at 10:30

2.1.6. - [EMA/OD/0000007338](#)

Treatment of uveal melanoma

Action: For adoption, Oral explanation to be held on 06 November 2019 at 13:00

2.1.7. - [EMA/OD/0000013557](#)

Treatment of haematopoietic stem cell transplantation

Action: For adoption, Oral explanation to be held on 06 November 2019 at 14:30

2.1.8. - [EMA/OD/0000004414](#)

Treatment of sickle cell disease

Action: For adoption, Oral explanation to be held on 06 November 2019 at 17:00

2.2. For discussion / preparation for an opinion

2.2.1. - [EMA/OD/0000005940](#)

Treatment of myasthenia gravis

Action: For discussion/adoption

2.2.2. - [EMA/OD/0000007445](#)

Treatment of acute myeloid leukaemia

Action: For discussion/adoption

2.2.3. - [EMA/OD/0000009960](#)

Treatment of osteosarcoma

Action: For discussion/adoption

2.2.4. - [EMA/OD/0000010610](#)

Treatment of autoimmune haemolytic anaemia

Action: For discussion/adoption

2.2.5. - EMA/OD/0000014201

Treatment of congenital alpha-1 antitrypsin deficiency

Action: For discussion/adoption

2.2.6. - EMA/OD/0000014361

Treatment of cystinuria

Action: For discussion/adoption

2.2.7. - EMA/OD/0000014371

Treatment of pancreatic cancer

Action: For discussion/adoption

2.2.8. - EMA/OD/0000015485

Treatment of multiple system atrophy

Action: For discussion/adoption

2.2.9. - EMA/OD/0000015678

Treatment of Fabry disease

Action: For discussion/adoption

2.2.10. - EMA/OD/0000015943

Treatment of tenosynovial giant cell tumour

Action: For discussion/adoption

2.2.11. - EMA/OD/0000016160

Treatment of Gaucher disease

Action: For discussion/adoption

2.2.12. - EMA/OD/0000016202

Treatment of phenylalanine hydroxylase deficiency

Action: For discussion/adoption

2.2.13. - EMA/OD/0000016302

Treatment of sickle cell disease

Action: For discussion/adoption

2.2.14. - EMA/OD/0000016345

Treatment of myelofibrosis

Action: For discussion/adoption

2.2.15. - EMA/OD/0000016360

Treatment of amyotrophic lateral sclerosis

Action: For discussion/adoption

2.2.16. - EMA/OD/0000016622

Treatment of ovarian cancer

Action: For discussion/adoption

2.2.17. - EMA/OD/0000016648

Treatment of pancreatic cancer

Action: For discussion/adoption

2.2.18. - EMA/OD/0000016718

Treatment of primary hepatocellular carcinoma (PHC)

Action: For discussion/adoption

2.3. Revision of the COMP opinions

None

2.4. Amendment of existing orphan designations

None

2.5. Appeal

2.5.1. naltrexone - EMA/OD/0000020985

Able AB; Treatment of fibromyalgia

Action: For adoption, Oral explanation to be held on 6 November 2019 at 09:00

2.6. Nominations

2.6.1. New applications for orphan medicinal product designation - Appointment of COMP rapporteurs

Action: For adoption

Document(s) tabled:

OMPD applications - appointment of coordinators at the 05-07 November 2019 COMP meeting

2.7. Evaluation on-going

Fourteen applications for orphan designation will not be discussed as evaluation is ongoing.

Action: For information

Notes:

See 7.8.1. Table 6. Evaluation Ongoing.

3. Requests for protocol assistance with significant benefit question

3.1. Ongoing procedures

3.1.1. -

Treatment of glioma

Action: For adoption

3.2. Finalised letters

3.2.1. -

Treatment of gastrointestinal stromal tumours

Action: For information

3.2.2. -

Treatment of graft-versus-host disease

Action: For information

3.2.3. -

Treatment of Duchenne muscular dystrophy

Action: For information

3.2.4. -

Treatment of amyotrophic lateral sclerosis

Action: For information

3.2.5. -

Treatment of congenital adrenal hyperplasia

Action: For information

3.3. New requests

3.3.1. -

Treatment of eosinophilic esophagitis

Action: For information

3.3.2. -

Treatment of C3 glomerulopathy

Action: For information

4. Review of orphan designation for orphan medicinal products at time of initial marketing authorisation

4.1. Orphan designated products for which CHMP opinions have been adopted

None

4.2. Orphan designated products for discussion prior to adoption of CHMP opinion

4.2.1. Revlimid – lenalidomide - EMEA/H/C/000717/II/0107, EMA/OD/158/12, EU/3/12/1097, EMA/OD/0000005466

Celgene Europe BV; Treatment of follicular lymphoma

CHMP rapporteur: Alexandre Moreau; CHMP co-rapporteur: Filip Josephson

Action: For discussion

4.2.2. – Osilodrostat - EMEA/H/C/004821, EMA/OD/099/14, EU/3/14/1345, EMA/OD/0000003092

Novartis Europharm Limited; Treatment of Cushing's syndrome

Action: For discussion

4.2.3. – enasidenib - EMEA/H/C/004324, EMA/OD/253/15, EU/3/16/1640, EMA/OD/0000007422

Celgene Europe B.V.; Treatment of acute myeloid leukaemia

Action: For information

4.3. Appeal

None

4.4. On-going procedures

Action: For information

Document(s) tabled:

Review of orphan designation for OMP for MA - On-going procedures

4.5. Orphan Maintenance Reports

Action: For information

5. Review of orphan designation for authorised orphan medicinal products at time marketing authorisation extension

5.1. After adoption of CHMP opinion

None

5.2. Prior to adoption of CHMP opinion

5.2.1. Darzalex – daratumumab - EMEA/H/C/004077/II/0030, EMA/OD/038/13, EU/3/13/1153, EMA/OD/0000010020

Janssen-Cilag International NV; Treatment of plasma cell myeloma

CHMP rapporteur: Sinan B. Sarac Jiménez; CHMP co-rapporteur: Jorge Camarero

Action: For discussion

5.3. Appeal

None

5.4. On-going procedures

Action: For information

Document(s) tabled:

Review of orphan designation for OMP for MA extension - On-going procedures

6. Application of Article 8(2) of the Orphan Regulation

None

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the COMP

7.1.1. Strategic Review & Learning meeting – joint COMP/CAT/PDCO, 21-22 November 2019, Helsinki, Finland

Update

Action: For information

Document(s) tabled:

Draft Agenda 21.11.2019 – PDCO/COMP/CAT

7.1.2. Protocol Assistance Working Group (PAWG)

Proposed meeting time on 5 November 2019 at 18:30 in room 0H

Action: For information

Document tabled:

PAWP draft agenda for 5 November 2019 meeting

7.2. Coordination with EMA Scientific Committees or CMDh-v

7.2.1. Recommendation on eligibility to PRIME – report

Action: For information

Document(s) tabled:

PRIME eligibility requests - list of adopted outcomes October 2019

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Working Party with Patients' and Consumers' Organisations (PCWP)

Action: For information

7.3.2. Working Party with Healthcare Professionals' Organisations (HCPWP)

Action: For information

7.4. Cooperation within the EU regulatory network

7.4.1. European Commission

None

7.5. Cooperation with International Regulators

7.5.1. Food and Drug Administration (FDA)

Action: For information

Notes: Monthly teleconference

7.5.2. Japanese Pharmaceuticals and Medical Devices Agency (PMDA)

Action: For information

Notes: Ad hoc basis meeting

7.5.3. Therapeutic Goods Administration (TGA), Australia

Action: For information

Notes: Ad hoc basis meeting

7.5.4. Health Canada

Action: For information

Notes: Ad hoc basis meeting

7.6. Contacts of the COMP with external parties and interaction with the Interested Parties to the Committee

None

7.7. COMP work plan

COMP work plan 2020

Action: For discussion

Document tabled:

Draft work plan 2020

7.8. Planning and reporting

7.8.1. List of all applications submitted/expected and the COMP rapporteurship distribution of valid applications submitted in 2019

Action: For information

7.8.2. Overview of orphan marketing authorisations/applications

Action: For information

8. Any other business

None

9. Explanatory notes

The notes below give a brief explanation of the main sections and headings in the COMP agenda and should be read in conjunction with the agenda or the minutes.

Abbreviations / Acronyms

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

EC: European Commission

OD: Orphan Designation

PA: Protocol Assistance

PDCO: Paediatric Committee

PRAC: Pharmacovigilance and Risk Assessment Committee

SA: Scientific Advice

SAWP: Scientific Advice Working Party

Orphan Designation (*section 2 Applications for orphan medicinal product designation*)

The orphan designation is the appellation given to certain medicinal products under development that are intended to diagnose, prevent or treat rare conditions when they meet a pre-defined set of criteria foreseen in the legislation. Medicinal products which get the orphan status benefit from several incentives (fee reductions for regulatory procedures (including protocol assistance), national incentives for research and development, 10-year market exclusivity) aiming at stimulating the development and availability of treatments for patients suffering from rare diseases.

Orphan Designations are granted by Decisions of the European Commission based on opinions from the COMP. Orphan designated medicinal products are entered in the Community Register of Orphan Medicinal Products.

Protocol Assistance (*section 3 Requests for protocol assistance with significant benefit question*)

The protocol assistance is the help provided by the Agency to the sponsor of an orphan medicinal product, on the conduct of the various tests and trials necessary to demonstrate the quality, safety and efficacy of the medicinal product in view of the submission of an application for marketing authorisation.

Sponsor

Any legal or physical person, established in the Community, seeking to obtain or having obtained the designation of a medicinal product as an orphan medicinal product.

Maintenance of Orphan Designation (*section 4 Review of orphan designation for orphan medicinal products for marketing authorisation*).

At the time of marketing authorisation, the COMP will check if all criteria for orphan designation are still met. The designated orphan medicinal product should be removed from the Community Register of Orphan Medicinal Products if it is established that the criteria laid down in the legislation are no longer met.

More detailed information on the above terms can be found on the EMA website:

www.ema.europa.eu/